1. Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin 
G. Drusano 
Clinical Microbiology and Infection 
Volume 7, Pages (January 2001)
DOI: /j s3024.x
Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

2. Fig 1
Plasma concentration-time profile of telithromycin after single and 10 days' once-daily administration of 800 mg to 12 healthy young subjects [12]. ery-R, erythromycin resistant; ery-S, erythromycin susceptible; peni-R, penicillin resistant; LOQ, limit of quantification.
Clinical Microbiology and Infection 2001 7, 24-29DOI: ( /j s3024.x)
Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

3. Fig 2
Telithromycin plasma concentration-time profile following an oral 800 mg dose of telithromycin taken after either an overnight fast or a standard high-fat breakfast [14].
Clinical Microbiology and Infection 2001 7, 24-29DOI: ( /j s3024.x)
Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

4. Fig 3
Mean concentration of telithromycin in epithelial lining fluid (ELF) and plasma following telithromycin 800 mg once daily for 5 days in 24 healthy volunteers [17].
Clinical Microbiology and Infection 2001 7, 24-29DOI: ( /j s3024.x)
Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions